tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000920148 /10-K filed Feb 24, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
VRTXHSICDVALHREGNVTRS
NYSE Health care · Medical Labs

Labcorp LH

LH quote by TradingView

Labcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. 10-K, Item 1

Headquarters
Burlington, NC
CEO
Adam H. Schechter
Next results
around Feb 16, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $14.0B through the costs to a net profit of $876.5M · income statement of the 10-K

10% operating margin
Revenue to Gross profit: $4.0BRevenue to Cost of revenue: $9.9BGross profit to Operating profit: $1.4BGross profit to Operating expenses: $2.6BOperating profit to Net profit: $876.5MOperating profit to Tax & other: $508.2M Revenue: $14.0B REVENUE $14.0B +7% Y/Y Gross profit: $4.0B · 29% margin GROSS PROFIT $4.0B 29% margin · +11% Y/Y Cost of revenue: $9.9B · 71% of revenue COST OF REVENUE $9.9B 71% of revenue Operating profit: $1.4B · 10% margin OPERATING PROFIT $1.4B 10% margin · +27% Y/Y Operating expenses: $2.6B · 19% of revenue OPERATING EXPENSES $2.6B 19% of revenue Net profit: $876.5M · 6% margin NET PROFIT $876.5M 6% margin · +17% Y/Y Tax & other: $508.2M · 4% of revenue TAX & OTHER $508.2M 4% of revenue
Gross profit $4.0B 29% margin · +11% Y/Y
Operating profit $1.4B 10% margin · +27% Y/Y
Net profit $876.5M 6% margin · +17% Y/Y
The full income statement, year by year

LH among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 7.2%, above 53% of 59 peers (their median 7.1%) REVENUE GROWTH 7.2% · above 53% Gross margin: 29.0%, above 12% of 50 peers (their median 65.2%) GROSS MARGIN 29.0% · above 12% Operating margin: 10.3%, above 34% of 50 peers (their median 13.7%) OPERATING MARGIN 10.3% · above 34% Net margin: 6.9%, above 39% of 59 peers (their median 9.7%) NET MARGIN 6.9% · above 39% FCF margin: 8.8%, above 29% of 55 peers (their median 15.8%) FCF MARGIN 8.8% · above 29% Return on capital: 6.5%, above 17% of 41 peers (their median 9.2%) RETURN ON CAPITAL 6.5% · above 17%
LH Peer median Below the median

What changed

26 new risk paragraphs. 10-K filed Feb 24, 2026 against Feb 25, 2025.

Risk factors
26 new paragraphs, nothing like them in the previous 10-K
10-K Item 1A
Accounting checks
11 other checks clear
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
10 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 11 checks found nothing to note

  • Receivables +8.2% vs revenue +7.2% (+1.0 pts)
  • Cash from operations $1.6B vs net income $876.5M (FY ending Dec 31, 2025)
  • Inventory +8.4% vs revenue +7.2% (+1.2 pts)
8 more checks with nothing to note
  • Same auditor in both 10-Ks: Deloitte & Touche LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • The same matters as last year: Valuation of Labcorp Diagnostics (Dx) Segment Net Accounts Receivable; F-2
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

26 paragraphs in Risk Factors that were not in the 10-K filed Feb 25, 2025. Quoted as filed.

All 26 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    Natural disasters (e.g., severe weather, fires, and earthquakes), geopolitical events (e.g., terrorism, war, and political instability), public health crises, criminal activity, supply chain disruptions, and other events beyond the Company’s control could negatively affect the Company’s operations. These disruptions may temporarily…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    The Company’s diagnostic testing services are primarily billed to third parties, including MCOs, employer plans, and other health insurance providers. A shift toward a higher mix of government and MCO payers may adversely effect revenues due to lower reimbursement rates. Ongoing efforts by payers to reduce reimbursement, tighten payment…
  3. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    BLS supports pharmaceutical, biotechnology, and medical device companies in navigating the regulatory approval and post-approval compliance requirements process. Changes in government regulations, whether easing or tightening requirements and changes in government operations, including staff reductions and reorganization efforts, could…
  4. Item 1A · new paragraph · not in the 10-K filed Feb 25, 2025 10-K, ITEM 1A
    BLS’s revenues are closely tied to R&D spending by pharmaceutical, biotechnology, and medical device companies, which may depend on access to capital and reimbursement from payers. Economic conditions, industry trends, or funding constraints could lead to reduced or delayed R&D activity or outsourcing, materially impacting BLS’s…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$11.9B$12.2B$13.0B$14.0B
Net income$1.3B$418.0M$746.0M$876.5M
Operating cash flow$2.0B$1.3B$1.6B$1.6B
Free cash flow$1.5B$874.1M$1.1B$1.2B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$14.0B ▲ 7.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

10 filings in the last 30 days · SEC EDGAR

All filings
5 more

About the company

Labcorp, Burlington, NC · from the 10-K filed Feb 24, 2026

Labcorp® Holdings Inc. is a global leader of innovative and comprehensive laboratory services that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. The Company provides insights and accelerates innovations to improve health and improve lives through its unparalleled diagnostics and drug development laboratory capabilities. During 2025, the Company’s nearly 71,000 employees served clients in approximately 100 countries and performed more than 750 million tests for patients around the world.

Headquarters
Burlington, NC
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 28, 2026

Email alerts

Sources

The 10-K filed Feb 24, 2026 (open at SEC), compared with the 10-K filed Feb 25, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LH/export.csv") into a cell.